Asim Kumar Bag

Asim Kumar Bag

Auto-generated profile, based on publicly available information

Asim Kumar Bag

Department of Radiology, St. Jude Children’s Research Hospital , Memphis, Tennessee

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Radiology
Verified
Journal Article
Open access
ABAsim K Bag
Asim K Bag
SGSanthosh Gaddikeri
Santhosh Gaddikeri
ASAparna Singhal
Aparna Singhal
SHSimms Hardin
Simms Hardin
BTBenson D Tran
Benson D Tran
JCJoel K Curé
Joel K Curé
Imaging of the temporomandibular joint: An update

6 June 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
BGBrian J Gebhardt
Brian J Gebhardt
MDMichael C Dobelbower
Michael C Dobelbower
WEWilliam H Ennis
William H Ennis
ABAsim K Bag
Asim K Bag
JMJames Markert
James Markert
JFJohn B Fiveash
John B Fiveash
To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide. We hypothesize that patients treated with margins in accordance with Adult Brain Tumor Consortium guidelines (ABTC) will demonstrate patterns of failure consistent with previous series of patients treated with 2–3 cm margins.

18 March 2010 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ABA.K. Bag
A.K. Bag
JCJ.K. Curé
J.K. Curé
PCP.R. Chapman
P.R. Chapman
GRG.H. Roberson
G.H. Roberson
RSR. Shah
R. Shah
SUMMARY: Since its initial description, there have been significant changes in the epidemiology, pathogenesis, and clinical and imaging manifestations of JCV infection of brain. The most common clinical manifestation is PML. Other recently described CNS manifestations are JCE, JCVGCN, and JCM. Although AIDS is the most common predisposing factor for JCV reactivation, there is increasing incidence of brain manifestations of JCV reactivation in non-HIV settings, including different rheumatologic, hematologic, and oncologic conditions; monoclonal antibody therapy; transplant recipients; primary immunodeficiency syndromes; and even in patients without any recognizable immune deficiency. IRIS may develop secondary to restoration of immunity in HIV-positive patients with PML receiving antiretroviral therapy. This is of profound clinical significance and needs to be diagnosed promptly. Imaging plays a crucial role in the diagnosis of the disease, monitoring of treatment response, identifying disease progression, and predicting prognosis. In this article, current understanding of the epidemiology, pathogenesis, clinical presentations, and all aspects of imaging of JCV infection of the brain have been comprehensively reviewed.

1 March 2011 in American Journal of Roentgenology
Verified
Journal Article
Closed access
PCPhilip R. Chapman
Philip R. Chapman
RSRitu Shah
Ritu Shah
JCJoel K. Curé
Joel K. Curé
ABAsim K. Bag
Asim K. Bag

26 May 2022 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
JBJoshua Bernstock
Joshua Bernstock
SGSam E Gary
Sam E Gary
NKNeil Klinger
Neil Klinger
PVPablo A Valdes
Pablo A Valdes
WEWalid Ibn Essayed
Walid Ibn Essayed
GFGregory Friedman
Gregory Friedman
Glioblastoma (GBM) is the most common primary adult intracranial malignancy and carries a dismal prognosis despite an aggressive multimodal treatment regimen that consists of surgical resection, radiation, and adjuvant chemotherapy. Radiographic evaluation, largely informed by magnetic resonance imaging (MRI), is a critical component of initial diagnosis, surgical planning, and post-treatment monitoring. However, conventional MRI does not provide information regarding tumor microvasculature, necrosis, or neoangiogenesis. In addition, traditional MRI imaging can be further confounded by treatment-related effects such as pseudoprogression, radiation necrosis, and/or pseudoresponse(s) that preclude clinicians from making fully informed decisions when structuring a therapeutic approach. A myriad of novel imaging modalities have been developed to address these deficits. Herein, we provide a clinically oriented review of standard techniques for imaging GBM and highlight emerging technologies utilized in disease characterization and therapeutic development.

15 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESElizabeth Scribner
Elizabeth Scribner
OSOlivier Saut
Olivier Saut
PPPaula Province
Paula Province
ABAsim Bag
Asim Bag
TCThierry Colin
Thierry Colin
HFHassan M. Fathallah-Shaykh
Hassan M. Fathallah-Shaykh
Glioblastoma multiforme (GBM) causes significant neurological morbidity and short survival times. Brain invasion by GBM is associated with poor prognosis. Recent clinical trials of bevacizumab in newly-diagnosed GBM found no beneficial effects on overall survival times; however, the baseline health-related quality of life and performance status were maintained longer in the bevacizumab group and the glucocorticoid requirement was lower. Here, we construct a clinical-scale model of GBM whose predictions uncover a new pattern of recurrence in 11/70 bevacizumab-treated patients. The findings support an exception to the Folkman hypothesis: GBM grows in the absence of angiogenesis by a cycle of proliferation and brain invasion that expands necrosis. Furthermore, necrosis is positively correlated with brain invasion in 26 newly-diagnosed GBM. The unintuitive results explain the unusual clinical effects of bevacizumab and suggest new hypotheses on the dynamic clinical effects of migration by active transport, a mechanism of hypoxia-driven brain invasion.